Catalyst Brief

← Calendar

Readoutin 76d

Epizyme, Inc. — Tazemetostat

Phase 3 primary completion: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma..

Date
Feb 2027
Type
Readout
Indication
Relapsed/Refractory Follicular Lymphoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.